Transcriptionally targeted gene therapy.
Hart
I R
IR
Richard Dimbleby Department of Cancer Research, Rayne Institute, St. Thomas Hospital, London, UK.
D000276:Adjuvants, Immunologic / Q000235:genetics; D000818:Animals; D001711:Biotransformation / Q000235:genetics; D004790:Enzyme Induction; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D008543:Melanins / Q000096:biosynthesis; D008545:Melanoma / Q000473:pathology; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy; D051379:Mice; D014442:Monophenol Monooxygenase / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011355:Prodrugs / Q000493:pharmacokinetics; D011401:Promoter Regions, Genetic; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D008543:Melanins; D009363:Neoplasm Proteins; D011355:Prodrugs; D011993:Recombinant Fusion Proteins; D014442:Monophenol Monooxygenase